Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

Here is my list of three expert market predictions for May 2025, including insights on yields and job market trends. Read ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Also Read: Viking Therapeutics, Structure Therapeutics Positioned ... respectively. Price Action: LLY stock is up 1.14% at $739.26, NVO stock is up 1.68% at $65.82, ALT stock is up 3.40% at ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound ...

Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects. This year ...

Now, it’s worth noting Stock Advisor ’s total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don’t miss out on the latest top 10 list ...

Viking Therapeutics (NASDAQ ... Why investors are bullish on the stock It's not hard to see why this company, which currently has a market cap of around $2.5 billion, can become a lot more ...